ESMO Breast Cancer 2025 Industry Satellite Symposium
Unlocking the Oncotype DX Breast Recurrence Score® Test: Unique design and development to bring clarity to treatment decisions
ESMO Breast Cancer 2025
Key Messages from the Exact Sciences Symposium
Professor Marc A. Thill: Welcome and Introduction
Professor Frédérique Penault-Llorca: Unlocking the Oncotype DX Breast Recurrence Score® Test: Unique design and development to bring clarity to treatment decisions
Professor Christos Sotiriou: Emerging Trends on Treatment Guidance in Early Breast Cancer: Unveiling clinical implications from latest updates from TAILORx and RxPONDER
Professor Marc A. Thill: Advancing Treatment Approaches and Neoadjuvant Therapy in Early Breast Cancer: Evidence-based strategies
19th St. Gallen International Breast Cancer Conference
Key Messages from the Exact Sciences Symposium
Professor Shani Paluch-Shimon: Optimizing systemic treatment choices using the Oncotype DX BreastRecurrence Score Result pre-operatively
Professor, Stephen Chia MD, FRCP(C): Directing Neoadjuvant Chemotherapy (NAC) using the Oncotype DXBreast Recurrence Score Result
Mr Henry Cain: Genomic testing on excision sample vs core biopsy: What we can learn from PreDX?
Patient perspectives: A round table discussion with Prof. Stephen Chia, Prof. Shani Paluch Shimon, and Mr Henry Cain
Webinars et vidéos disponibles à la demande
ESMO 2024 Satellite symposium recording
[ESMO24] Evolving role of genomic assays in early breast cancer
Prof. Miguel Martin discusses the application of genomic assays in the neoadjuvant setting[ESMO24] Tissue-based genomics to guide adjuvant therapy decisions
Prof. Janice Walshe discusses the impact of the introduction of genomic assays on clinical practice for both clinicians and patients.[ESMO24] Introduction to MRD in breast cancer
Prof. Nicholas Turner provides a brief overview of the concept and terms related to molecular residual disease.[ESMO24] Evolving role of MRD guided decision making in early breast cancer
Prof. Sherene Loi presented at ESMO 2024 an update on the current data and ongoing studies on molecular residual disease in early breast cancer.[ESMO24] Optimizing the approach to MRD assay development
Rick Baehner provides a topline overview of ongoing research into the development of MRD assays.EBCC 2024 Satellite symposium recording
[EBCC24] Evolving clinical practice for multi-gene assays: what’s new!
Evolving clinical practice for multi-gene assays: what’s new![EBCC24] Implications of updated guidelines for MGAs: Introduction
Implications of updated guidelines for MGAs: Introduction[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour
Implementation of guidelines into clinical practice: expert discussion on challenging cases - Large tumour[EBCC24] Implementation of guidelines into clinical practice: expert discussion on challenging cases - Elderly patient
Professor Laura Biganzoli presented a challenging case study of an elderly patient with early breast cancer, focusing on the important interplay between genomic tools and patients’ characteristics.[EBCC24] Challenging cases: N1 – premenopausal
Professor Christian Kurzeder presented a challenging case study of a N1 premenopausal patient, focusing on how ODX and clinical evidence may help...Other webinar and event recordings
Premiers résultats de l'essai RxPONDER dans la pratique clinique: Qu'est-ce qui va changer ?
Le Professeur Stephen Chia de l'Université de Colombie-Britannique, au Canada, et le Dr Mark Verrill des hôpitaux de Newcastle on Tyne, au ...

La pratique clinique revisitée: Améliorer les décisions de traitement par chimiothérapie dans les cas de cancer du sein à un stade précoce
Le professeur Hartkopf de l'université de Tübingen expose des preuves issues de sa pratique clinique et des paramètres qui guident les décisions de...

Le test Oncotype DX Breast Recurrence Score en pratique Clinique
Le Professeur Maccon Keane de Saolta University Health Care Group affilié à l'hôpital universitaire de Galway en Irlande présente les validations ...

Optimisez les résultats du traitement du cancer du sein à un stade précoce grâce à une utilisation personnalisée de la chimiothérapie
Suivez la discussion d'un groupe d'experts lors de la Conférence internationale sur le cancer du sein de Saint-Gallen 2019 sur les preuves sur la ...

Contactez-nous
Vous avez des questions sur Oncotype DX ?
